Lupin Limited, an innovation led transnational pharmaceutical company, announced the launch of the United States Food and Drug Administration (FDA) approved abacavir and lamivudine tablets, 600 mg/300 mg
Lupin’s abacavir and lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Epzicom tablets had US sales of US$ 388.1 million (IMS MAT December 2016).
Lupin introduces generic, epzicom tablets, us market
